Market Overview

Horizon to Acquire US Rights for VIMOVO from Pozen

Related POZN
What Should Biotech Investors Do Now?
Top Performing Industries For June 22, 2015

announced that AstraZeneca AB (NYSE: AZN) and Horizon Pharma USA, Inc. (NASDAQ: HZNP) have entered into an agreement for Horizon to acquire the U.S.
rights for VIMOVO® (naproxen / esomeprazole magnesium)
delayed release tablets. Under the terms of the agreement, POZEN will
continue to receive a 10% royalty on Net Sales of products sold in the
United States, with guaranteed annual minimum royalty payments of $5
million in 2014, and $7.5 million each year thereafter, provided that
the patents owned by POZEN which cover VIMOVO® are in effect
and no generic forms of VIMOVO® are on the market. Also under
the agreement, Horizon has assumed AstraZeneca's right to lead the

See full press release

Posted-In: News Guidance Contracts Management M&A Global


Related Articles (AZN + HZNP)

Get Benzinga's Newsletters